Following Joseph Vinhais’ last IART Sell transaction on March 12, 2018, the stock climbed by 5.6%. In addition to Joseph Vinhais, 4 other IART executives reported Sell trades in the last month.
Based on Integra Lifesciences’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $384 million and quarterly net profit of $29.74 million. In comparison, last year the company earned revenue of $366 million and had a net profit of $11.38 million. The company has a one-year high of $66.41 and a one-year low of $42.14. Currently, Integra Lifesciences has an average volume of 464.94K.
The insider sentiment on Integra Lifesciences has been negative according to 69 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments.